What is the recommended workup and management for cold agglutinin disease?

Cold Agglutinin Disease: Workup and Management

For suspected cold agglutinin disease (CAD), confirm diagnosis with monospecific direct antiglobulin test (DAT) positive for C3d (but negative for IgG), cold agglutinin titer ≥1:64 at 4°C, evidence of hemolysis, and bone marrow evaluation to document clonal B-cell lymphoproliferative disorder. 1, 2

Diagnostic Workup

Essential Laboratory Tests

The diagnostic approach requires specific testing performed under strict temperature control:

• Complete blood count with peripheral smear - Look for anemia, macrocytosis, and evidence of hemolysis 3
• Hemolysis markers: LDH, haptoglobin, indirect bilirubin, reticulocyte count 3, 2
• Monospecific DAT - Must show C3d positivity with IgG negativity (this distinguishes CAD from warm autoimmune hemolytic anemia) 1, 2
• Cold agglutinin titer - Performed at 4°C; diagnostic threshold is ≥1:64 1, 4, 2
• Thermal amplitude testing - Better predictor of clinical severity than titer alone 2

Critical pre-analytical requirement: All blood samples must be collected and maintained at 37°C until serum separation to prevent false results 1

Additional Workup

• Protein electrophoresis and immunofixation - Identifies monoclonal IgM-κ in most cases 3
• Cryoglobulin analysis - Present in up to 20% of patients 5
• Bone marrow biopsy with flow cytometry - Documents clonal B-cell lymphoproliferative disorder; required to distinguish primary CAD from secondary cold agglutinin syndrome 1, 2
• Infectious workup - Screen for Mycoplasma, EBV, CMV to exclude secondary causes 3, 2

Exclude Secondary Causes

CAD must be differentiated from cold agglutinin syndrome (CAS), which occurs secondary to infections, lymphoma, or other disorders. If underlying malignancy or active infection is identified, treat the primary condition rather than managing as primary CAD 2.

Management Algorithm

Immediate Supportive Measures

• Avoid cold exposure - Environmental temperature control is fundamental 4, 6
• Maintain adequate hydration during hemolytic crises 4
• Thrombosis prophylaxis - CAD carries elevated thromboembolic risk 4, 2
• Transfusion support when necessary - Use blood warmer; transfuse only minimum units needed to reach hemoglobin 7-8 g/dL 3
• Folic acid supplementation 1 mg daily 3

Definitive Treatment Selection

Corticosteroids and splenectomy are ineffective and NOT recommended for CAD 7, 2. This is a critical distinction from warm autoimmune hemolytic anemia.

First-Line Options:

For patients requiring treatment (symptomatic hemolysis, disabling cold-induced symptoms, or severe anemia):

1. Complement inhibition with sutimlimab (anti-C1s antibody) - Only approved therapy; provides rapid response within days with improvement in hemolysis and fatigue 4, 2

   • Mandatory prerequisite: Comprehensive vaccination against encapsulated bacteria (pneumococcus, meningococcus, Haemophilus influenzae) with bridging antibiotic prophylaxis until immunity achieved 4
   • Most effective for complement-mediated hemolytic phenotype 8

2. B-cell directed therapy with rituximab - Median response duration 24 months; 55% require no further treatment 6

   • Can be combined with complement inhibition, though optimal sequencing requires further study 7, 8

3. Rituximab plus chemotherapy combinations - For patients with more aggressive disease or inadequate response to single-agent rituximab 7

Treatment Ineffective in CAD:

• Corticosteroids (long-term use discouraged due to side effects without benefit) 9, 7, 2
• Splenectomy 7, 2

Special Considerations

For patients with predominant non-hemolytic symptoms (acrocyanosis, cold-induced circulatory symptoms): These are agglutinin-dependent rather than complement-dependent, so B-cell directed therapy targeting the clonal population may be more appropriate than complement inhibition alone 2, 8

Pain management: Address this systematically as it significantly impacts quality of life, though often overlooked 9

Procedural precautions: During any procedures requiring blood handling (transfusions, apheresis, stem cell collection), maintain strict temperature control with environmental warming and insulation of extracorporeal components 10

Common Pitfalls to Avoid

• Do not use polyspecific DAT alone - Must use monospecific antisera to confirm C3d positivity and IgG negativity 1
• Do not handle samples at room temperature - This causes false results; maintain 37°C throughout 1
• Do not treat with corticosteroids as first-line - Unlike warm AIHA, steroids are ineffective in CAD 7, 2
• Do not overlook vaccination requirements before starting complement inhibition - Risk of severe infection with encapsulated organisms 4